Biguanide (Klinischer Teil)

Mehnert, Hellmut; Haese, E

doi:10.1007/978-3-642-65265-3_9

Cited by 6 publications

(2 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data derived from [17] indicate that biguanide consumption in France, for 1975, was 92,054 kg metformin and 1,418 kg phenformin; assuming a mean daily intake of 2 g metformin or 0.1 g phenformin per patient, 165000 patients may have been on biguanide therapy in France that year: 76% of them on metformin and 24% on phenforrain, a very different proportion from certain other countries [18,19]. Metformin is approximately 20 times less active than phenformin [20]; this much lower hypoglycaemic potency is believed to be due (. )…”

Section: Discussionmentioning

confidence: 99%

Metformin-induced lactic acidosis in the presence of acute renal failure

et al. 1977

View full text Add to dashboard Cite

Lactic acidosis occourred in 6 metformintreated diabetic patients. Five of them had received 1.6 to 2.4 g metformin per day over a period of weeks or years. Acute renal failure, induced by i. v. pyelography, arteriography, or severe dehydration, preceded lactic acidosis by a few days and apparently precipitated it. The sixth patient had normal renal function prior to taking a massive overdose of metformin in an attempt at suicide. The metabolic pattern was very similar to that observed in phenformin-induced lactic acidosis: severe metabolic acidosis (pH: 7.02 + 0.95; HCO~: 6.3 + 0.9 mmol/l; PaCO2:25 _+ 4mmHg; PaO2:110 + 19 mmHg); hyperlactataemia (18.4 + 3.3 retool/l) and high lactate/pyruvate ratio (51 _+ 5); high blood alanine (2.82 + 1.10 mmol/1); high 3-hydroxybutyrate (15.8 + 3.3 mmol/1) and high 3-hydroxybutyrate/ acetoacetate ratio (26 + 10). Hypoglycaemia (25 to 60 mg per 100 ml) was observed in 4 patients, in spite of high glucagon (760 _+ 148 pg/ml) and low insulin (13 + 5 ~tU/ml) levels. A guanidine substance was characterized in the plasma at concentrations 45 to 110 ~tg/ml; it was similar to metformin and distinct from creatinine, according to chromatographic and other criteria; its concentration in the plasma decreased during dialysis, and the same substance appeared in the dialysis effluent. The treatment included massive alkalinization (710 ___ 130 mmol/1 i. v. for 48 h), plasma volume expanders (5630 + 1000 ml/48 h), forced-diuresis and/or dialysis, insulin (30 +_ 10 U/48 h) and glucose (300 _+ 50 g/48 h). -It is concluded that: 1. metformin, like other biguanides, can induce lactic acidosis; 2. acute renal failure is a prominent causal factor; 3. pharmacokinetics of metformin account for this fact since metformin cannot be inactivated by the liver (as distinct from phenformin) and is normally excreted by the kidney; 4. accumulation of biguanide is suggested by guanidine assay in the plasma; 5. metformin should not be prescribed in the presence of renal failure.

show abstract

Section: Discussionmentioning

confidence: 99%

Metformin-induced lactic acidosis in the presence of acute renal failure

et al. 1977

View full text Add to dashboard Cite

show abstract

“…Another two biguanides, phenformin (phenethylbiguanide) [2] and buformin (butylbiguanide) have been used since 1957 [1] and 1958 [3], respectively. Phenformin was widely used in the 1960s and early 1970s [4] but its association with lactic acidosis and the associated mortality led to its withdrawal in several countries [5,6]. It is still available in China, Mexico and a few European countries [7].…”

Section: Metformin: the Current Widely Prescribed Biguanidementioning

confidence: 99%